stockrowIDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.
- Revenue
- −95.1%
- EPS
- −190.5%
- Free cash flow
- −165.9%
Quarter to September 2026, against a year earlier
Follow IDYA
Alert me
IDEAYA Biosciences, Inc. (IDYA) Return on invested capital
IDEAYA Biosciences, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −114.2%, down 88.2 percentage points from fiscal 2025 (−26.0%). Over the past ten years it has ranged from −1,916.2% (fiscal 2019) to 0.00% (fiscal 2022); the current reading is higher than 56% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −26.0% | 27.42 |
| FY2024 | −53.4% | 34.16 |
| FY2023 | −87.5% | (87.54) |
| FY2022 | 0.00% | 57.39 |
| FY2021 | −57.4% | (57.39) |
| FY2020 | 0.00% | 1,916.16 |
| FY2019 | −1,916.2% | (1,916.16) |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | 0.00% |
| TARS Tarsus Pharmaceuticals, Inc. compare | 0.00% |
| VRDN Viridian Therapeutics, Inc. compare | 0.00% |
| CELC Celcuity, Inc. compare | 0.00% |
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| DNLI Denali Therapeutics Inc. compare | −80.0% |
| IDYA IDEAYA Biosciences, Inc. | −114.2% |
| DYN Dyne Therapeutics, Inc. compare | −1,956.3% |
| BEAM Beam Therapeutics Inc. compare | −2,676.9% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on IDYA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement